The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent dilution. PubMed: 19699272
1/2000. Predicted molecular weight: 78 kDa.
PathwayMetabolic intermediate metabolism; propanoyl-CoA degradation; succinyl-CoA from propanoyl-CoA: step 1/3.
Involvement in diseaseDefects in PCCA are the cause of propionic acidemia type I (PA-1) [MIM:606054]. PA-1 is a life-threatening disease characterized by episodic vomiting, lethargy and ketosis, neutropenia, periodic thrombocytopenia, hypogammaglobulinemia, developmental retardation, and intolerance to protein.
Propionyl CoA carboxylase alpha chain mitochondrial antibody
Propionyl CoA carboxylase alpha polypeptide antibody
Propionyl coenzyme A carboxylase alpha polypeptide antibody
Propionyl-CoA carboxylase alpha chain antibody
Anti-PCCA antibody images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PCCA antibody (ab16307)Image from Ballhausen D et al., Neuroscience. 2009;164(2):578-87. Fig 3.; doi: 10.1016/j.neuroscience.2009.08.028 with permission from Elsevier.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of adult rat brain labelling PCCA with ab16307. A - cortex. (B) - hippocampus, (C) - caudate putamen. Bar: 100 μm.
References for Anti-PCCA antibody (ab16307)
This product has been referenced in:
Ballhausen D et al. Evidence for catabolic pathway of propionate metabolism in CNS: expression pattern of methylmalonyl-CoA mutase and propionyl-CoA carboxylase alpha-subunit in developing and adult rat brain. Neuroscience164:578-87 (2009).
Read more (PubMed: 19699272) »